Can pediatric steroid-free renal transplantation improve growth and metabolic complications?

Area of Science:

• Nephrology
• Pediatric Transplant Surgery
• Immunosuppression Therapy

Background:

• Steroids are commonly used in pediatric renal transplantation but associated with adverse effects.
• Evaluating steroid avoidance protocols is crucial for improving long-term outcomes in pediatric kidney transplant patients.

Purpose of the Study:

• To assess the efficacy and safety of a steroid avoidance protocol in pediatric renal transplant recipients.
• To compare outcomes including calculated creatinine clearance (CrCl), cytomegalovirus (CMV) infection, cholesterol levels, and growth parameters (height, weight, BMI Z scores) between steroid-free and steroid-treated groups.

Main Methods:

• A case-control trial comparing 19 pediatric renal transplant recipients (age 1-20 years) on a steroid-free immunosuppression regimen (tacrolimus, mycophenolate mofetil, daclizumab) with 30 contemporaneous controls receiving steroids.
• Patients were matched for follow-up duration, donor type, age, immunosuppression type, sex, transplant date, original disease, and CMV status.
• Outcomes including graft survival, CrCl (Schwartz), CMV disease, cholesterol, and Z scores for height, weight, and BMI were analyzed at one year post-transplant.

Main Results:

• One-year graft survival was 100% in both the steroid-free and control groups.
• Mean CrCl (Schwartz) at one year was not significantly different between the groups.
• CMV disease occurred in 7/30 control patients but in 0/19 steroid-free patients.
• Height delta Z scores were similar, while weight and BMI delta Z scores were significantly higher in the steroid-free group.
• Cholesterol levels differed but remained within normal ranges for both groups.

Conclusions:

• Steroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab in pediatric renal transplant recipients achieves equivalent or superior outcomes compared to traditional steroid-based protocols.
• This steroid avoidance strategy demonstrates a significant reduction in CMV disease incidence without compromising graft function or growth parameters at one year.